Top 20 life sciences deals of 2025 show a bigger-bet market
PharmaShots has published its Top 20 Life Sciences Deals of 2025 in partnership with DealForma, highlighting a year shaped by fewer but larger transactions across biopharma, diagnostics, and platform technologies. The list spans acquisitions, licensing agreements, and business-unit sales, from Shionogi’s roughly $2.5 billion purchase of Mitsubishi Tanabe Pharma’s RADICAVA business to large oncology and platform deals such as Pfizer’s more than $6 billion collaboration with 3SBio and Bristol Myers Squibb’s BioNTech partnership around BNT327. DealForma’s broader 2025 review shows the same pattern: healthcare and life sciences M&A reached 585 transactions worth about $269.3 billion, nearly double 2024 by value, while R&D partnerships generated $273.6 billion despite lower deal count, pointing to a market that favored scaled, commercially relevant, or strategically differentiated assets. That same preference showed up in financing, too: PharmaShots’ Top 20 Healthcare IPOs of 2025 said investors gravitated toward scaled platforms, AI-enabled solutions, precision medicine, and revenue-generating healthcare businesses, with Medline Industries leading at $7.2 billion and Caris Life Sciences and Lumexa Imaging among the next-largest raises. (pharmashots.com, pharmashots.com)
Why it matters: For veterinary professionals, this isn’t a companion animal story on its face, but it is a useful signal about where capital, platform interest, and commercial infrastructure are moving across health care. Big-money activity around rare disease, oncology, neuroscience, AI-enabled discovery, bispecific antibodies, and data platforms can influence talent flows, manufacturing capacity, diagnostic innovation, and investor expectations that eventually touch animal health. The 2025 pattern also suggests buyers paid up for de-risked assets and late-stage or revenue-generating products, while cross-border licensing, especially involving Chinese biopharma, remained a major theme. Large pools of specialist capital are still being raised as well: Blackstone closed its $6.3 billion BXLS VI fund at its hard cap, making it the largest life sciences vehicle of its kind and reinforcing that well-funded investors still have appetite for drug and medtech opportunities. (pharmashots.com, pharmashots.com)
What to watch: Watch whether 2026 dealmaking spills further into animal health, diagnostics, and veterinary-adjacent technologies as strategics and large funds keep looking for de-risked growth and platform assets. Also watch whether private equity and late-stage buyers continue to support rare disease and specialty pharma at scale, as seen in CVC Capital Partners’ proposed roughly €10.9 billion take-private of Recordati and Eli Lilly’s planned approximately $7.8 billion acquisition of Centessa Pharmaceuticals to expand in sleep medicine and neuroscience. (dealforma.com, pharmashots.com, pharmashots.com)